Finasteride: Male Baldness Obsession Soars
Between 2017 and 2024, finasteride prescriptions in the United States tripled — and the numbers keep climbing in 2026. What was once a medication quietly prescribed by dermatologists for men over 40 has transformed into a cultural phenomenon reaching young men aged 19, 20, and 21, many of them with no visible signs of hair loss. Telehealth platforms ship pills in minimalist packaging, TikTok influencers record "before and after" videos with millions of views, and the pharmaceutical industry rakes in billions while the European Medicines Agency warns that the drug can lead patients to consider taking their own lives.
This is the story of how baldness stopped being accepted as a natural part of aging and became a condition to be fought with urgency — and at what cost.
What Happened
Finasteride 1 mg, originally marketed under the brand name Propecia by Merck, received FDA approval in 1997 for the treatment of male androgenetic alopecia. For two decades, the medication occupied a relatively stable niche in the dermatological market. Everything changed starting in 2017, when telehealth platforms like Hims in the United States, Manual in the United Kingdom, and Hair+Me in continental Europe began offering quick online consultations and discreet delivery of finasteride directly to patients' doors.
The business model of these companies is simple and efficient: a man fills out an online questionnaire, a licensed physician reviews the answers in minutes, and the prescription is issued without the need for a physical examination or in-person consultation. The pills arrive in sleek packaging with no labels identifying the contents, eliminating the embarrassment many men felt when seeking hair loss treatment at traditional pharmacies.
The numbers reflect this transformation. Data compiled by Men's Health UK and corroborated by National Health Service surveys show that the volume of searches for finasteride in the United Kingdom exceeds 75,000 monthly queries. In the United States, the tripling of prescriptions between 2017 and 2024 represents millions of new users, many of them in their twenties.
The phenomenon is not limited to the English-speaking world. In Brazil, dermatologists report a significant increase in demand for finasteride among university students, and Brazilian telehealth clinics already offer the medication with monthly subscription models similar to those of American platforms. Across Europe and Asia, the same pattern is emerging — young men turning to finasteride earlier and earlier, often without any clinical indication of significant hair loss.
Background and Context
To understand the finasteride explosion, one must go back to the biochemistry of male baldness. Androgenetic alopecia affects approximately 50 percent of men by age 50 and about 80 percent by age 70. The mechanism is well documented: the enzyme 5-alpha-reductase type II converts testosterone into dihydrotestosterone (DHT), which binds to receptors on genetically sensitive hair follicles, causing progressive miniaturization of the hair strands until the follicle stops producing visible hair.
Finasteride blocks this enzyme, reducing DHT levels in the scalp by 60 to 70 percent. Clinical data published in peer-reviewed journals, including the Journal of the American Academy of Dermatology and studies indexed in PubMed by the National Institutes of Health (NIH), demonstrate that approximately 90 percent of men who used finasteride 1 mg daily maintained or increased their hair count over two years.
These numbers are impressive and explain part of the medication's appeal. However, the story of finasteride is not solely one of clinical success. The drug was originally developed at a 5 mg dose to treat benign prostatic hyperplasia, and its approval for baldness at the reduced 1 mg dose always carried caveats about side effects.
For years, the medical community treated these effects as rare and reversible. Merck's clinical trials indicated that between 2 and 4 percent of users experienced some degree of sexual dysfunction — loss of libido, erectile difficulty, or reduced ejaculatory volume — and that these symptoms disappeared upon discontinuation.
This narrative began to be questioned in the early 2010s, when a growing number of men reported that side effects persisted for months or even years after they stopped taking the medication. In 2012, the Post-Finasteride Syndrome Foundation (PFS Foundation) was formally established to document and research these cases. The foundation maintains a patient registry and funds studies at American and European universities.
The controversy gained institutional weight when the European Medicines Agency (EMA) conducted a safety review and concluded that finasteride is capable of causing suicidal ideation in patients. The agency mandated that medication labels across the entire European Union be updated to include this warning. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) followed a similar path.
Impact on the Public
The impact of the finasteride explosion manifests across multiple dimensions — economic, psychological, cultural, and public health. The table below summarizes the key transformations observed between the previous and current landscape.
| Aspect | Before (pre-2017) | After (2024-2026) | Impact |
|---|---|---|---|
| Access to medication | In-person consultation required | Telehealth in minutes, discreet delivery | Millions of new users, many without adequate follow-up |
| Predominant age group | Men over 35 | Young men aged 18 to 25 | Preventive use before any signs of baldness |
| Cultural perception of baldness | Accepted as natural aging | Treated as a condition to be fought | Increased male anxiety about appearance |
| Risk information | Medical labels and dermatologist consultations | Influencers and social media ads | Minimization of side effects, misinformation |
| Global hair treatment market | Estimated at $3 billion | Projected to reach $13 billion by 2028 | Pharmaceutical and telehealth industries in rapid expansion |
| Regulatory oversight | Occasional label warnings | EMA warns of suicidal ideation, BBC investigates influencers | Growing pressure for stricter regulation |
The economic dimension is revealing. The global hair loss treatment market, which includes finasteride, minoxidil, hair transplants, and laser therapies, was worth approximately $3 billion before the pandemic. Projections from consulting firms like Grand View Research and Allied Market Research indicate this market should surpass $13 billion by 2028, driven precisely by telehealth and the normalization of treatment among young men.
In the mental health arena, the impact is dual and paradoxical. On one hand, men suffering from early baldness report significant improvement in self-esteem and quality of life when they regain hair with finasteride. On the other, the very obsession with hair appearance generates anxiety, and the medication's side effects can worsen depressive conditions.
The PFS Foundation documents hundreds of cases of men who developed persistent sexual dysfunction, severe depression, and cognitive fog after using finasteride. Although the mainstream medical community still debates the prevalence and causality of these symptoms, studies published in the Journal of Sexual Medicine and the Journal of Clinical Endocrinology and Metabolism have identified neurosteroid alterations in patients with persistent symptoms, suggesting that finasteride may affect brain biochemistry in ways not yet fully understood.
For young men in their twenties, the decision to take finasteride involves a particularly complex risk calculation. They are at the peak of their sexual and reproductive lives, and the potential side effects — even if statistically rare — can have devastating consequences at this stage. At the same time, social pressure to maintain a youthful appearance has never been more intense, amplified by selfies, video calls, and the visual culture of social media.
What Stakeholders Are Saying
The polarization around finasteride is evident in the statements of the different actors involved.
Dermatologists who regularly prescribe the medication tend to emphasize its proven efficacy and the low incidence of side effects in clinical trials. The prevailing position among dermatology societies is that finasteride remains a safe and effective option for most patients, provided there is adequate medical follow-up.
Telehealth platforms argue they are democratizing access to men's health. Hims, which went public on the New York Stock Exchange and reached a market valuation exceeding $2 billion, argues that its online screening protocols are rigorous and that the convenience of the service encourages men who would never seek in-person help to take care of their health.
On the opposite side, the PFS Foundation and affected patient groups accuse the pharmaceutical industry and telehealth platforms of minimizing serious risks. They point out that the few-minute online consultation model does not allow adequate assessment of the patient's psychiatric history, a relevant factor given the EMA's warning about suicidal ideation.
The BBC investigation brought another concerning aspect to light: the illicit advertising of hair treatments by social media influencers. The British broadcaster documented cases of content creators on TikTok who promoted finasteride and other treatments without disclosing commercial ties to clinics or telehealth platforms. As a result of the investigation, TikTok removed three hair loss influencer accounts for violating its advertising policies.
Public health researchers warn of what they call the medicalization of masculinity. The argument is that the industry is transforming a natural variation in male appearance — baldness — into a medical condition requiring continuous pharmaceutical treatment, creating economic and psychological dependence in millions of men.
What Comes Next
The outlook for the coming years points to an intensification of the debate on several fronts.
On the regulatory front, pressure on agencies like the FDA, EMA, and their counterparts worldwide is expected to increase. Patient organizations and lawmakers in several countries are calling for more robust long-term studies on the effects of finasteride, especially in young users. The possibility of requiring more detailed informed consent, including explicit warnings about psychiatric and sexual risks, is under discussion in health committees in the European Union and the United Kingdom.
Hair-focused telehealth is expected to continue growing, but with greater scrutiny. Regulators in several countries are evaluating whether the quick online consultation model is adequate for prescribing medications with a side effect profile like finasteride's. In the United Kingdom, the Care Quality Commission has already signaled its intention to audit telehealth platforms that prescribe finasteride at scale.
In the scientific arena, ongoing research seeks to better understand the mechanism of Post-Finasteride Syndrome. Studies using functional MRI and neurosteroid analysis in cerebrospinal fluid are being conducted at universities in the United States and Italy. If these studies confirm persistent neurological alterations, the regulatory and legal impact will be significant.
Alternatives to finasteride are also in development. Topical treatments with DHT inhibitors that act locally on the scalp without significant systemic absorption are in advanced clinical trial phases. Platelet-rich plasma (PRP) therapy and microneedling with minoxidil are gaining followers as options with a lower risk profile. Biotech companies are working on stem cell-based therapies for follicular regeneration, although these are still far from commercial availability.
The Economic Dimension: Who Profits from Hair Obsession
The global hair loss treatment market reveals a value chain that extends far beyond finasteride. Hims & Hers Health, the American company that went public on the New York Stock Exchange, reported revenues exceeding $1 billion in 2024, with finasteride as one of its best-selling products. The British company Manual, operating in the UK and Europe, raised hundreds of millions in venture capital funding rounds. In Brazil and across Latin America, men's telehealth startups follow the same model, offering monthly subscriptions that include finasteride, minoxidil, and hair supplements.
The subscription model is particularly lucrative because finasteride requires continuous use to maintain results. If the patient stops treatment, hair loss returns within months. This creates a recurring customer base that generates predictable revenue — the dream of any health tech company. A man who starts taking finasteride at 22 and continues until 50 will spend tens of thousands of dollars over his lifetime on the medication alone, not counting consultations, tests, and complementary treatments.
The hair transplant market also benefits from the normalization of treatment. Clinics in Turkey, which has become the world's number one destination for hair transplants, report a 30 percent annual increase in international patients. Many of these patients started with finasteride and minoxidil before opting for the surgical procedure, creating a consumption funnel that begins with a pill and ends on an operating table.
The Role of Social Media in Normalizing Treatment
TikTok, Instagram, and YouTube have become the primary vectors for spreading hair treatment culture among young men. Hashtags like #finasteride, #hairloss, and #hairtransplant accumulate billions of combined views on these platforms. Content creators document their treatment journeys in video series spanning months or years of finasteride use, showing comparative "before and after" photos that function as extremely effective advertising.
The algorithms of these platforms amplify the phenomenon. A 20-year-old man who searches once about hair loss begins receiving a continuous stream of content about hair treatments, transplant clinics, and telehealth platforms. The repetition creates the perception that treatment is universal, safe, and necessary — even for those who show no signs of baldness.
The BBC investigation that resulted in the removal of three TikTok influencer accounts revealed concerning practices. Some content creators received payment from clinics and telehealth platforms without disclosing the commercial relationship, violating advertising regulations in several countries. Others made medical claims without qualification, minimizing side effects or promising results not guaranteed by the scientific literature.
The phenomenon is not limited to individual influencers. Telehealth companies invest heavily in targeted social media advertising, using segmentation algorithms to reach young men who show interest in appearance, fitness, or personal care. The ads are sophisticated, combining medical language with emotional appeal, and frequently offer discounts for the first consultation or the first month of treatment, creating a conversion funnel that transforms aesthetic concern into a monthly medication subscription.
The consequence is a generation of men growing up believing that baldness is a medical condition requiring early pharmaceutical intervention, rather than a natural variation in male appearance that can be accepted, treated, or ignored according to individual preference. The line between health information and pharmaceutical marketing has never been thinner.
Closing Thoughts
The tripling of finasteride prescriptions in less than a decade is not merely a pharmaceutical statistic. It reflects a profound transformation in men's relationship with their bodies, their appearance, and their mental health. Telehealth technology removed barriers to access, but it also removed safety filters. Social media democratized information, but it also amplified misinformation and aesthetic pressure.
The 22-year-old man who today fills out an online questionnaire and receives finasteride at home is making a medical decision with potential implications for decades of his life — often based on 60-second TikTok videos and targeted Instagram ads. The medication's efficacy is real and documented. The risks are also real and documented. The challenge for society, regulators, and each individual is finding the balance between the right to treat a condition that causes genuine suffering and the responsibility not to turn normality into pathology.
Baldness has always existed. What changed is what we decided to do about it — and who profits from that decision.
Sources and References
- Men's Health UK — Finasteride prescriptions and telehealth growth
- BBC Investigation — TikTok hair loss influencer accounts removed
- European Medicines Agency (EMA) — Finasteride safety review
- Post-Finasteride Syndrome Foundation
- NIH/PubMed — Clinical data on finasteride efficacy
- Newser — Finasteride prescription trends 2017-2024
